NEW YORK (GenomeWeb News) – Sequenom today said that it has extended the term of its supply agreement with Illumina from three to five years.
The pact now terminates in July 2016. Further terms of the agreement were not disclosed.
Under the terms of the deal, signed last July, Sequenom and its subsidiaries agreed to purchase sequencing equipment and consumables from Illumina for use in developing its non-invasive trisomy 21 test. In addition, the firms said at the time that they intend to work collaboratively toward the submission of regulatory clearance of an in vitro diagnostic test for detecting fetal chromosomal abnormalities.
Sequenom launched its MaterniT21 test, which employs Illumina's HiSeq platform, in October.